HRH3 and Alzheimer disease: In addition, another clinical study was carried out with ABT-288, a highly selective H3R antagonist/inverse agonist, demonstrating no efficacy of ABT-288 in the symptomatic treatment of subjects with mild-to-moderate AD (Haig et al., 2014b).